NDAORALPELLETSPriority Review
Approved
Jun 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
Priority Review
MAVYRET (glecaprevir and pibrentasvir) by AbbVie is p-glycoprotein inhibitors [moa]. Approved for hepatitis c. First approved in 2021.
Drug data last refreshed 19h ago
Mechanism of Action
P-Glycoprotein Inhibitors
Pharmacologic Class:
Hepatitis C Virus NS5A Inhibitor
Indications (1)
Clinical Trials (1)
Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C
Started Feb 2017
10 enrolled
Chronic Kidney DiseaseChronic Hepatitis C
Company
Worked on MAVYRET at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.